Last reviewed · How we verify

ART0380 — Competitive Intelligence Brief

ART0380 (ART0380) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DNA repair inhibitor. Area: Oncology.

phase 2 DNA repair inhibitor DPC (DNA-protein crosslink) repair pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ART0380 (ART0380) — Artios Pharma Ltd. ART0380 is a DNA-protein crosslink (DPC) repair inhibitor that enhances the activity of DNA damaging agents by preventing cellular repair of crosslinks.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ART0380 TARGET ART0380 Artios Pharma Ltd phase 2 DNA repair inhibitor DPC (DNA-protein crosslink) repair pathway
O6-benzylguanine O6-benzylguanine Case Comprehensive Cancer Center phase 3 DNA repair inhibitor / Alkyltransferase inhibitor O6-alkylguanine-DNA alkyltransferase (AGT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DNA repair inhibitor class)

  1. Artios Pharma Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ART0380 — Competitive Intelligence Brief. https://druglandscape.com/ci/art0380. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: